MTCH
37
7
CMCSA
48
2
HD
47
-5
LLY
39
9
IBM
54
4
VRSN
53
3
INTC
35
-2
DHR
35
3
AMGN
44
5
PSA
51
-4
IP
70
2
GIS
26
3
URI
53
-2
HRB
51
2
DLTR
34
-4
ACN
47
-2
EXPE
88
2
UHS
54
3
MUR
43
3
PRU
57
-3
MTCH
37
7
CMCSA
48
2
HD
47
-5
LLY
39
9
IBM
54
4
VRSN
53
3
INTC
35
-2
DHR
35
3
AMGN
44
5
PSA
51
-4
IP
70
2
GIS
26
3
URI
53
-2
HRB
51
2
DLTR
34
-4
ACN
47
-2
EXPE
88
2
UHS
54
3
MUR
43
3
PRU
57
-3
Financhill
Back

Takeda Pharmaceutical 10K Form

Sell
20

TAK
Takeda Pharmaceutical

Last Price:
13.30
Seasonality Move:
3.79%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive TAK News And Ratings

See the #1 stock for the next 7 days that we like better than TAK

TAK Financial Statistics

Sales & Book Value

Annual Sales: $29.55B
Cash Flow: $1.28B
Price / Cash Flow: 12.53
Annual Sales: $15.29
Price / Book: 0.89

Profitability

EPS (TTM): 0.60440
Net Income (TTM): $1.93B
Gross Margin: $19.66B
Return on Equity: 4.01%
Return on Assets: 1.91%

Takeda Pharmaceutical Earnings Forecast

Key Takeda Pharmaceutical Financial Ratios

  • The Gross Profit Margin over the past 25 years for TAK is 66.54%.
  • The Selling, General & Administrative Expenses for TAK have been equal to 24.72% of Gross Profit Margin.
  • The Research & Development expenses have been 17.12% of Revenue.
  • The Interest Expense is 82.97% of Operating Income.
  • The Net Earning history of TAK is 3.38% of Total Revenues.
  • Per Share Earnings over the last 25 years have been positive in 15 years.

Takeda Pharmaceutical Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: TAK
CUSIP: 874060
Website: takeda.com

Debt

Debt-to-Equity Ratio: 0.73
Current Ratio: 1.28
Quick Ratio: 0.68

Price-to-Earnings

Trailing P/E Ratio: 42.83
Forward P/E Ratio: 0

TAK Technical Analysis vs Fundamental Analysis

Sell
20
Takeda Pharmaceutical (TAK) is a Sell

Is Takeda Pharmaceutical a Buy or a Sell?